Precision Biosciences Inc (DTIL)

$8.20 +0.34 (4.33%)
Market Cap 202.80M
Revenue (ttm) 34.26M
Net Income (ttm) -45.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -133.45%
Debt to Equity Ratio 0.29
Volume 203,600
Avg Vol 289,796
Day's Range N/A - N/A
Shares Out 25.80M
Stochastic %K 97%
Beta 1.31
Analysts Strong Sell
Price Target $32.00

Company Profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with t...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 314 5512
Fax: 480 393 5553
Address:
302 East Pettigrew St., Suite A-100, Durham, United States
Madchemist0827
Madchemist0827 May. 13 at 2:42 PM
$DTIL https://iecure.com/wp-content/uploads/ASGCT-2026_iECURE_Presentation.pdf
0 · Reply
Madchemist0827
Madchemist0827 May. 13 at 2:41 PM
$DTIL https://iecure.com/news/iecure-presents-preliminary-clinical-data-from-ongoing-clinical-trial-of-ecur-506-in-ornithine-transcarbamylase-deficiency-at-the-asgct-annual-meeting/
0 · Reply
SkywalkerAR
SkywalkerAR May. 12 at 10:13 AM
$DTIL what's happens? any news?
1 · Reply
Takesonetoknowone
Takesonetoknowone May. 6 at 1:43 PM
$DTIL why can’t I buy ffs
1 · Reply
Estimize
Estimize May. 5 at 11:49 AM
$DTIL reported - EPS and 10.84 revenue for Q1. http://www.estimize.com/intro/dtil?chart=historical&metric_name=eps&utm_content=DTIL&utm_med
0 · Reply
LoveRetailFroth
LoveRetailFroth May. 1 at 1:27 PM
$AMLX Good Morning ☕️ Bio 💎s $SMMT $RXRX $SANA $DTIL
0 · Reply
Norbertoni
Norbertoni Apr. 29 at 5:21 PM
$DTIL thin biotech action, risk changes fast if volume expands
0 · Reply
DARKP00L
DARKP00L Apr. 29 at 11:31 AM
$DTIL 07:11 on Apr. 29 2026 Precision Biosciences Starts Phase 1/2 FUNCTION-DMD Study Of PBGENE-DMD, In Vivo Gene Editing Treatment For Duchenne Muscular Dystrophy #tradeideas
0 · Reply
JVDBNL
JVDBNL Apr. 29 at 11:11 AM
$DTIL https://www.stocktitan.net/news/DTIL/precision-bio-sciences-activates-first-clinical-trial-site-and-ve3d8xek50vc.html
0 · Reply
DARKP00L
DARKP00L Apr. 28 at 12:37 PM
$DTIL 08:14 on Apr. 28 2026 iECURE To Present Clinical Data From Ongoing ECUR-506 Trial Using Precision Bioscience's ARCUS Nuclease At American Society Of Gene & Cell Therapy Annual Meeting May 11-15 #tradeideas
1 · Reply
Latest News on DTIL
Precision BioSciences sees cash runway through 2028

2026-05-05T11:37:34.000Z - 8 days ago

Precision BioSciences sees cash runway through 2028

Precision BioSciences reports Q1 EPS (75c) vs. ($2.21) last year

2026-05-05T11:24:42.000Z - 8 days ago

Precision BioSciences reports Q1 EPS (75c) vs. ($2.21) last year

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026, 7:01 AM EDT - 8 days ago

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

Apr 30, 2026, 7:01 AM EDT - 13 days ago

Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

Precision BioSciences activates first clinical trial site for PBGENE-DMD

2026-04-29T11:25:37.000Z - 14 days ago

Precision BioSciences activates first clinical trial site for PBGENE-DMD

Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

Apr 29, 2026, 7:01 AM EDT - 14 days ago

Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

Precision BioSciences announces oral presentation at ASGCT 2026

2026-04-28T12:25:50.000Z - 15 days ago

Precision BioSciences announces oral presentation at ASGCT 2026

Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

Apr 28, 2026, 7:01 AM EDT - 15 days ago

Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

Precision BioSciences announces grant of inducement awards

2026-04-24T11:11:38.000Z - 19 days ago

Precision BioSciences announces grant of inducement awards

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Apr 24, 2026, 7:01 AM EDT - 19 days ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026

Apr 22, 2026, 7:01 AM EDT - 21 days ago

Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026

Precision BioSciences assumed with a Buy at JonesResearch

2026-04-16T20:14:10.000Z - 26 days ago

Precision BioSciences assumed with a Buy at JonesResearch

Precision BioSciences receives CTA approval to expand Eliminate-B trial

2026-04-15T11:22:22.000Z - 4 weeks ago

Precision BioSciences receives CTA approval to expand Eliminate-B trial

Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

Apr 15, 2026, 7:01 AM EDT - 4 weeks ago

Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

Precision BioSciences Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 9:30 AM EDT - 4 weeks ago

Precision BioSciences Transcript: 25th Annual Needham Virtual Healthcare Conference

Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 7:01 AM EDT - 5 weeks ago

Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

Precision BioSciences reports Q4 EPS $1.05, consensus (64c)

2026-03-12T11:46:49.000Z - 2 months ago

Precision BioSciences reports Q4 EPS $1.05, consensus (64c)

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

Mar 12, 2026, 7:00 AM EDT - 2 months ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

Precision receives two notices of allowance from USPTO for PBGENE-HBV

2026-03-11T11:40:52.000Z - 2 months ago

Precision receives two notices of allowance from USPTO for PBGENE-HBV

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

Mar 11, 2026, 7:01 AM EDT - 2 months ago

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

Precision BioSciences presents new PBGENE-DMD data at conference

2026-03-10T11:26:11.000Z - 2 months ago

Precision BioSciences presents new PBGENE-DMD data at conference

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

Mar 10, 2026, 7:01 AM EDT - 2 months ago

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

Mar 9, 2026, 4:15 PM EDT - 2 months ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

Precision BioSciences announces fast track designation for PBGENE-DMD

2026-03-09T11:18:17.000Z - 2 months ago

Precision BioSciences announces fast track designation for PBGENE-DMD

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

Mar 9, 2026, 7:01 AM EDT - 2 months ago

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

Precision to get $7.5M in proceeds from TG Therapeutics for azer-cel milestone

2026-03-02T12:24:58.000Z - 2 months ago

Precision to get $7.5M in proceeds from TG Therapeutics for azer-cel milestone

TGTX

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

Mar 2, 2026, 7:01 AM EST - 2 months ago

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

TGTX

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Feb 18, 2026, 7:01 AM EST - 3 months ago

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Precision BioSciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 3:30 PM EST - 3 months ago

Precision BioSciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

Feb 11, 2026, 7:01 AM EST - 3 months ago

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy

Jan 12, 2026, 7:01 AM EST - 4 months ago

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy

Precision BioSciences Transcript: Sidoti's Year End Virtual Investor Conference

Dec 11, 2025, 9:15 AM EST - 5 months ago

Precision BioSciences Transcript: Sidoti's Year End Virtual Investor Conference

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Nov 19, 2025, 7:01 AM EST - 6 months ago

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Precision BioSciences Transcript: Study Update

Nov 11, 2025, 8:00 AM EST - 6 months ago

Precision BioSciences Transcript: Study Update

Precision BioSciences announces $75M offering of common stock, warrants

2025-11-10T23:25:24.000Z - 6 months ago

Precision BioSciences announces $75M offering of common stock, warrants

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Nov 10, 2025, 6:12 PM EST - 6 months ago

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Precision BioSciences trading resumes

2025-11-10T23:00:14.000Z - 6 months ago

Precision BioSciences trading resumes

Precision BioSciences announces presentation from PBGENE-HBV study

2025-11-10T22:25:12.000Z - 6 months ago

Precision BioSciences announces presentation from PBGENE-HBV study

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

Nov 10, 2025, 5:21 PM EST - 6 months ago

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

Precision BioSciences trading halted, news pending

2025-11-10T21:55:10.000Z - 6 months ago

Precision BioSciences trading halted, news pending

Ten new option listings on November 5th

2025-11-05T13:30:28.000Z - 6 months ago

Ten new option listings on November 5th

AIS DRTS UNCY

Precision BioSciences reports Q3 EPS ($1.84), consensus ($2.21)

2025-11-03T12:11:18.000Z - 6 months ago

Precision BioSciences reports Q3 EPS ($1.84), consensus ($2.21)

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 7:01 AM EST - 6 months ago

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 31, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Precision BioSciences Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 21, 2025, 9:30 AM EDT - 7 months ago

Precision BioSciences Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Precision BioSciences Transcript: H.C. Wainwright Liver Disease Virtual Conference

Oct 21, 2025, 7:00 AM EDT - 7 months ago

Precision BioSciences Transcript: H.C. Wainwright Liver Disease Virtual Conference

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Oct 14, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Precision BioSciences Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Oct 14, 2025, 7:00 AM EDT - 7 months ago

Precision BioSciences Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Precision BioSciences publishes ARCUS nucleases data

2025-10-09T11:20:12.000Z - 7 months ago

Precision BioSciences publishes ARCUS nucleases data

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Oct 9, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Oct 7, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

Sep 30, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Sep 12, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Sep 8, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

Aug 6, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

Aug 4, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Jul 23, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

Jul 16, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Jun 25, 2025, 7:01 AM EDT - 11 months ago

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Precision BioSciences Transcript: Sidoti May Micro-Cap Virtual Conference

May 21, 2025, 3:15 PM EDT - 1 year ago

Precision BioSciences Transcript: Sidoti May Micro-Cap Virtual Conference

Precision BioSciences Transcript: Status Update

May 15, 2025, 8:00 AM EDT - 1 year ago

Precision BioSciences Transcript: Status Update

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 14, 2025, 4:30 PM EDT - 1 year ago

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

May 8, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

May 7, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 1, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Apr 15, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Precision BioSciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 3:00 PM EDT - 1 year ago

Precision BioSciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Mar 21, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Mar 20, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 19, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Mar 17, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Mar 12, 2025, 8:00 AM EDT - 1 year ago

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 24, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Feb 19, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Jan 29, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Madchemist0827
Madchemist0827 May. 13 at 2:42 PM
$DTIL https://iecure.com/wp-content/uploads/ASGCT-2026_iECURE_Presentation.pdf
0 · Reply
Madchemist0827
Madchemist0827 May. 13 at 2:41 PM
$DTIL https://iecure.com/news/iecure-presents-preliminary-clinical-data-from-ongoing-clinical-trial-of-ecur-506-in-ornithine-transcarbamylase-deficiency-at-the-asgct-annual-meeting/
0 · Reply
SkywalkerAR
SkywalkerAR May. 12 at 10:13 AM
$DTIL what's happens? any news?
1 · Reply
Takesonetoknowone
Takesonetoknowone May. 6 at 1:43 PM
$DTIL why can’t I buy ffs
1 · Reply
Estimize
Estimize May. 5 at 11:49 AM
$DTIL reported - EPS and 10.84 revenue for Q1. http://www.estimize.com/intro/dtil?chart=historical&metric_name=eps&utm_content=DTIL&utm_med
0 · Reply
LoveRetailFroth
LoveRetailFroth May. 1 at 1:27 PM
$AMLX Good Morning ☕️ Bio 💎s $SMMT $RXRX $SANA $DTIL
0 · Reply
Norbertoni
Norbertoni Apr. 29 at 5:21 PM
$DTIL thin biotech action, risk changes fast if volume expands
0 · Reply
DARKP00L
DARKP00L Apr. 29 at 11:31 AM
$DTIL 07:11 on Apr. 29 2026 Precision Biosciences Starts Phase 1/2 FUNCTION-DMD Study Of PBGENE-DMD, In Vivo Gene Editing Treatment For Duchenne Muscular Dystrophy #tradeideas
0 · Reply
JVDBNL
JVDBNL Apr. 29 at 11:11 AM
$DTIL https://www.stocktitan.net/news/DTIL/precision-bio-sciences-activates-first-clinical-trial-site-and-ve3d8xek50vc.html
0 · Reply
DARKP00L
DARKP00L Apr. 28 at 12:37 PM
$DTIL 08:14 on Apr. 28 2026 iECURE To Present Clinical Data From Ongoing ECUR-506 Trial Using Precision Bioscience's ARCUS Nuclease At American Society Of Gene & Cell Therapy Annual Meeting May 11-15 #tradeideas
1 · Reply
LoveRetailFroth
LoveRetailFroth Apr. 27 at 1:48 PM
$RXRX Good Morning ☕️ My gem💎s. $AMLX $SMMT $SANA $DTIL
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 24 at 5:51 PM
$DTIL RSI: 61.50, MACD: 0.4978 Vol: 0.83, MA20: 6.73, MA50: 5.74 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
focafoca99
focafoca99 Apr. 24 at 2:03 PM
$DTIL awards inducement RSUs covering 7,094 shares to a new employee.
0 · Reply
LoveRetailFroth
LoveRetailFroth Apr. 24 at 1:27 PM
$AMLX Good Morning 💎 s ☕️ $RXRX $SANA $SMMT $DTIL
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 22 at 6:07 PM
$DTIL Lets see what happens here when they report the 1st HBV cure
0 · Reply
Wolfman5960
Wolfman5960 Apr. 22 at 3:09 PM
$DTIL Late breaking poster presentation confirmed for EASL on May 27th for the HBV program: Title: "First evidence of elimination and inactivation of cccDNA in liver biopsies collected from patients with chronic hepatitis B treated with PBGENE-HBV" https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-late-breaking-poster-2
0 · Reply
Wolfman5960
Wolfman5960 Apr. 20 at 10:52 AM
$DTIL Next month should be interesting. The ASGCT conference is held from May 11-15 and the EASL Congress conference is May 27-30. iECURE will probably give an update at ASGCT and we should see an update from Precision for the HBV program at EASL.
0 · Reply
revuelto
revuelto Apr. 17 at 6:13 PM
$DTIL 🎉
0 · Reply
LoveRetailFroth
LoveRetailFroth Apr. 15 at 6:48 PM
$DTIL $70 🚀
0 · Reply
DARKP00L
DARKP00L Apr. 15 at 11:13 AM
$DTIL 07:11 on Apr. 15 2026 Precision BioSciences Receives Clinical Trial Application Approval To Expand Ongoing Global ELIMINATE-B Clinical Trial Of PBGENE-HBV #tradeideas
0 · Reply
LoveRetailFroth
LoveRetailFroth Apr. 14 at 12:33 PM
$SANA Good Morning 💎 s. $AMLX $RXRX $TEMT $DTIL ☕️
0 · Reply
DeepBlueTitan
DeepBlueTitan Apr. 10 at 12:14 PM
$DTIL
0 · Reply